As Recipharm continues to refine its footprint, the CDMO is selling its development and small-scale active pharmaceutical ingredient (API) manufacturing facility in Yavne, Israel, to Scinai ...

Frost & Sullivan is pleased to announce that Bioiberica has received the 2025 European New Product Innovation Recognition in the ...

The company said Tuesday that the FDA greenlit a supplemental new drug application for Wakix, a treatment for cataplexy, a narcolepsy symptom characterized by sudden muscle weakness, in pediatric ...

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...

The pharmaceutical manufacturing market is poised for growth by leveraging advanced technologies, digital platforms, and robust supply chain strategies. Opportunities arise in adopting ...

The pharmaceutical sector continues to witness earnings-driven momentum as companies report resilient Q3 FY26 performance, supported by strong domestic demand, export traction, and improved ...

Natco Pharma's Q3 consolidated net profit rose 14.3% YoY to ₹152 crore, while revenue increased by 36.3%, driven by higher export formulations and other operating income.

Opinion: Freedom-to-operate analysis must be understood as a continuous, integrated process that evolves alongside science, regulation, and commercial strategy.

New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and ...

According to multiple recent market analyses, the global API market is experiencing steady growth. One comprehensive forecast ...

The Fine and Specialty Chemicals Market is entering a transformative phase of high-value innovation and application-specific customization, underpinned by specialty chemicals’ critical role as ...

Market valued at $16.86B in 2024, projected 4.20% CAGR growth driven by VOC regulation compliance, bio-based adoption, ...